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Abstract
Many cationic antimicrobial peptides (AMPs) target the unique lipid composition of the prokaryotic cell membrane.
However, the micromolar activities common for these peptides are considered weak in comparison to nisin, which follows a
targeted, pore-forming mode of action. Here we show that AMPs can be modified with a high-affinity targeting module,
which enables membrane permeabilization at low concentration. Magainin 2 and a truncated peptide analog were
conjugated to vancomycin using click chemistry, and could be directed towards specific membrane embedded receptors
both in model membrane systems and whole cells. Compared with untargeted vesicles, a gain in permeabilization efficacy
of two orders of magnitude was reached with large unilamellar vesicles that included lipid II, the target of vancomycin. The
truncated vancomycin-peptide conjugate showed an increased activity against vancomycin resistant Enterococci, whereas
the full-length conjugate was more active against a targeted eukaryotic cell model: lipid II containing erythrocytes. This
study highlights that AMPs can be made more selective and more potent against biological membranes that contain
structures that can be targeted.
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Introduction
Antimicrobial peptides (AMPs) are crucial components of the
innate immune system that act predominantly at the level of the
plasma membrane of the bacterial cell [1,2]. Many AMPs have
both antimicrobial and anticancer activity, since membranes of
cancerous eukaryotic cells share features with those of prokaryotic
cells, i.e. a relatively high negative charge [3–5]. The magainin
peptides were discovered early and became the paradigm for the
mode of action for many cationic amphipathic AMPs [6,7].
However, this group of polypeptides lacks sufficient affinity for its
target membranes, and activity is commonly observed at
micromolar concentrations. This limits their medicinal use
because the effective dose is close to the toxic dose [8]. Increasing
the activity, or reducing the toxicity of AMPs may broaden this
therapeutic window and this is essential for the application of these
peptides in combating the growing resistance of antimicrobial
agents to pathogens, and may complement or enhance existing
anticancer therapies.
The mechanisms of action of AMPs in general have been
studied in great detail [9–11]. AMPs that are active against
eukaryotic cells may potentially be used in anticancer therapy,
although they also suffer from low selectivity and high toxicity. For
the magainins and other cationic AMPs, anionic structures in
cancer cell plasma membranes such as the lipid phosphatidyl
serine [12], and O-glycosylated mucins [13] may be responsible
for their attraction to the eukaryotic cell, and their cell
permeabilization activity [14]. However, a dramatic improvement
of the high micromolar activities requires a targeted mode of
action for cationic AMPs.
The nisin-lipid II system is to the best of our knowledge the most
active pore forming peptide system known. The first step of nisin’s
targeted pore forming mechanism involves the N-terminal part of
nisin, which specifically binds the pyrophosphate part of the lipid
II molecule [15–19]. Subsequently, C-terminus membrane inser-
tion and pore assembly occurs, which causes leakage of the cell
content. This process is 1000 times more efficient than AMPs that
rely predominantly on an electrostatic attraction to the cell
membrane [20]. Here we aimed to mimic the highly effective
targeted pore forming mechanism observed in nisin by conjuga-
tion of a high-affinity targeting moiety to an AMP. Such a system
could potentially be adapted to target various types of cells,
depending on the targeting moiety.
We focused to increase the membrane disrupting potency of two
peptides based on the magainin 2 sequence by linking a targeting
moiety (Figure 1). Vancomycin was chosen for targeting, since it
binds lipid II. As for the AMPs, we chose the full-length magainin
2 sequence, and compared it to a shorter optimized analog
sequence [21]. We observed a large targeting effect on large
unilamellar vesicles (LUVs) that contained lipid II. The conjugates
showed decreased activity with vancomycin susceptible bacterial
strains compared to vancomycin alone, but showed an increased
antimicrobial activity against vancomycin resistant Enterococci with
the shorter vancomycin-peptide conjugate. Strikingly, on eukary-
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permeabilzation of erythrocytes that contained lipid II with a
remarkably potency similarly to nisin. This result broadens the
applicability of targeted AMPs towards anticancer therapy and
shows that permeabilization of any eukaryotic cell of choice may
be possible, provided that the AMP can be specifically targeted to
the cell membrane.
Results and Discussion
We synthesized the conjugates using the highly efficient CuAAC
click chemistry. This reaction is the copper-mediated coupling
between an azide and an alkyne, and has been used in numerous
applications [22]. We coupled lysine bearing an azide on its side
chain to the N-terminus of these peptides on the solid phase [23].
Vancomycin was functionalized with an alkyne functional group
as previously reported [24]. Conjugation was achieved upon
dissolving the functionalized precursors in an aqueous solution
with addition of sodium ascorbate, CuSO4 and heating in the
microwave. Both conjugates were purified using HPLC (.98%,
Figure S1) and identified using mass spectrometry.
In order to test if vancomycin was indeed a good targeting
module for the peptide, the leakage of carboxyfluorescein was
measured from LUVs with a lipid composition that represented
the outer leaflet of the eukaryotic cell (60% DOPC:SM:DOPE
(46:42:12), 40% cholesterol), and compared this to similar vesicles
containing 0.1% lipid II. This lipid composition would give a clear
indication of the targeting ability of the vancomycin portion since
the cationic peptide would not be strongly attracted to the
zwitterionic head groups (phosphatidylcholine, and sphingomy-
elin). In this system, nisin caused leakage in vesicles that contained
lipid II at nanomolar concentrations, whereas vesicles that did not
contain lipid II required much higher concentrations (Figure 2).
We found that the vancomycin-magainin construct 1 caused
leakage with a similar potency to nisin, i.e. at low nanomolar
concentrations. Similarly, the shorter conjugate 2 caused lipid II
dependent leakage, although only a maximum of 20% leakage
could be achieved. Control experiments with unfunctionalized
magainin peptides tested on vesicles with or without lipid II, or the
targeted peptides and nisin tested on vesicles that did not contain
lipid II, all caused carboxyfluorescein leakage at the expected
micromolar concentrations. Previously reported data showed that
magainin 2 does not depend on lipid II content [19]. Our results
suggest that the length of the peptide may be important in this
vesicle system, which mimics the eukaryotic cell membrane.
Previous studies on similar AMPs of different length show that this
parameter is significant for the mode of action [25]. Shorter
peptides may tend to follow the carpet model [26] whereas longer
peptides at least have the potential for transmembrane orientation.
Compound 1, consisting of a peptide (24 amino acids), vancomy-
cin (7 amino acids) and a linker is approximately the same length
as nisin (34 amino acids). The shorter conjugate 2 gives
significantly less leakage. By conjugating magainin to a specific
targeting structure in this system, an improvement of approxi-
mately 100 fold was obtained.
Next the conjugates were tested on a small series of Gram-
positive bacteria including methicillin resistant S. aureus, (MRSA)
and vancomycin susceptible, and resistant Enterococci (VSE, and
VRE respectively) (Table 1). For the vancomycin-magainin
Figure 1. Synthesis of the vancomycin-targeted AMPs.
doi:10.1371/journal.pone.0039768.g001
Figure 2. Large unilamellar vesicles (25 mM) consisting of
(DOPC/DOPE/SM) (46/12/42) 60%, cholesterol (40%), and lipid
II (0.1%), which contained a solution of carboxyfluorescein
were treated with 1 (&), 2 (N) and nisin (m). Vesicles without lipid II
were treated with 1 (%), 2 (#) and magainin 2 (n).
doi:10.1371/journal.pone.0039768.g002
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susceptible Gram-positive strains. Vancomycin-lipid II binding
was probably slightly perturbed due to peptide modification, thus
compared to native vancomycin, a weaker inhibition was seen.
Other possibilities for reduced potency include the peptide
interaction with the negatively charged structures in the cell wall
such as the teichoic acids, or peptide aggregation within the cell
wall decreased accessibility of the vancomycin part to its target,
and negatively affected its potency. Interestingly, a significant gain
in activity was observed with conjugate 2 with VRE. In this case,
the contribution of the vancomycin component is much weaker,
revealing the effect of the peptide portion of the conjugate. In
contrast to the susceptible strains, peptide interaction with the cell
wall or membrane may lead here to increased concentrations
leading to an activity advantage. This effect may be comparable to
other glycopeptide analogs that contain a hydrophobic anchor to
target the membrane (oritavancin, televancin, dalbavancin).
Resistance to vancomycin (vanA or vanB type resistance) due to
a substitution of D-Lac for the terminal D-Ala residue results in a
decreased level of vancomycin binding and therefore decreased
efficacy. The N-terminal portion of nisin, nisin(1-12), should not
be susceptible to this mutation since it binds the pyrophosphate
portion of lipid II. We therefore synthesized a nisin(1-12)-
compound 5 conjugate and observed that this conjugate gave a
weaker activity (32 mg/mL) than compound 2 (16 mg/mL) (see
Methods S1, and Table S1). This is probably due to the relatively
weak binding ability of nisin(1-12) alone to Lipid II: Nisin(1-12)
alone gave activities of 128 mg/mL for both VSE and VRE.
This growth inhibition assay gave a good indication of the
biological activity in a living prokaryotic model system, although
moreVREisolatesshouldbetestedtovalidatetheactivityincreaseof
compound2.Inaddition,amorein-depthstudywouldbeneededto
fullyunderstandthemechanismofactioninthisbiologicalsystemand
rule out any additive effects the two components may have in
combination. This may include experiments such as the checker-
board assay to determine the sum of the fractional inhibitory
concentrations (SFIC), and would indicate the degree of synergy
between the targeting componentand the peptide component.This
couldbe comparedtoavirtualSFICcalculated usingtheminimum
inhibitory concentration (MIC) of the hybridized product for the
contributionofthecovalentlinkage.AvirtualSFICcalculatedusing
compound 2, and its two components was 0.19, giving a strong
synergistic effect (see Methods S1). Note that inour assay, we report
values with units mg/mL. Considering that the molecular weight of
the hybridized product is approximately twice that of its two
components, the observed gain of activity on a per molecule basis is
morepronounced.Asacontrolexperiment,thecompoundswerealso
tested on a Gram-negative strain, M. catarhallis. As expected, no
advantage was seen. Vancomycin is active only on Gram-positive
bacteria and needs lipid II or nascent peptidoglycan as accessible
targetstopreventcrosslinkinginthegrowingcellwall.Overall,these
results show that access to the plasma membrane may be inhibited.
However, access to the plasma membrane is not relevant with
eukaryotic cells, whichdo not have cell walls.
Finally, to test if the vancomycin-peptide conjugates were active
towards a eukaryotic model system, we doped erythrocytes with a
small amount of lipid II. Thiscell wall precursoris amphiphilic, and
prefers to be incorporated in any membrane. Lipid II was
incorporated into the membrane of human erythrocytes by rapidly
mixingasolutionoftheerythrocytesinPBSwithanethanolicsolution
oflipidII.Thepeptideconjugateswerethenaddedandhemolysiswas
observedbymeasuringthereleaseofhemoglobinintothesolution.In
this experiment, hemolysis would indicate a strong targeting effect.
Indeed, strongly enhanced hemolysis was seen by the vancomycin-
magainin conjugate 1 and by nisin with the lipid II containing
erythrocytes (Figure 3 and Figure S2). For nisin, the maximum
amount of hemolysis was 90–100%, which occurred between 5–
10 mM. Similarly, for the vancomycin-magainin conjugate 1 the
maximumhemolysiswasbetween60-80%,andoccurredbetween5-
10 mM.Incomparison,weobservednohemolysiswitherythrocytes
thatdidnotcontainlipidII,andnohemolysisofuntargetedmagainin
at concentrations up to 100 mM. The shorter conjugate 2 showed a
lipidII-dependentactivity,howeveronlyamaximumhemolysisofca.
20%could be reached.
Conclusion
The addition of a targeting moiety can lead to enhance pore
formation of model membranes, but this depends on the nature of
the AMP [27]. The remarkable properties of the targeted peptide
systems described here, namely, enhanced leakage with model
membranes, bacterial growth inhibition, and notable activity
towards a eukaryotic membrane reveals the versatility of such
peptide conjugates. The latter ability was observed with potency
comparable to nisin. This result shows the broader potential of
cationic AMPs such as magainin linked to high-affinity targeting
modules as potential therapeutics in anticancer applications where
both increased cell selectivity and high potency are crucial.
Materials and Methods
Antibacterials and Reagents
Vancomycin was obtained from Sigma (The Netherlands). Nisin
was purified from ChrisinH, which was generously donated from
Christian Hansen (Denmark). Electrospray ionization (ESI) mass
spectrometry was carried out using a Shimadzu LCMS QP-8000
singlequadrupolebenchtopmassspectrometer(m/zrange,2000),
coupled with a QP-8000 data system. Analytical HPLC was
performed on a Shimadzu Class-VP automated HPLC using an
analytical reversed-phase column (Alltech Adsorbosphere C18, 300
A ˚,5 m m,25064.6 mm)andaUVdetectoroperatingat220 nmand
254 nm. Preparative HPLC was performed on a Gilson automated
HPLCusingapreparativereversed-phasecolumn(AlltechAdsorbo-
sphere C18, 10 m m, 250622 mm) and a UV detector operating at
220 nm and 254 nm. Elution was effected using an appropriate
gradient from 0.1% TFA in CH3CN/H2O (5/95, v/v)(buffer A) to
0.1%TFAinCH3CN/H2O(95/5,v/v)(bufferB)usingaflowrateof
1 mL min.
21 (analytical) or 11.5 mL min.
21 (preparative). Micro-
wave reaction was performed in an Initiator reactor from Biotage.
Fluorescence measurements were performed on an SLM-Aminco
SPF-500 C fluorimeter.
Table 1. Minimum inhibitory concentration (MIC, mg/mL) of
vancomycin-magainin peptide derivatives.
Compound
a V
b 41 5 2
MRSA
c (15A761) 0.75 .256 32 256 2
MRSA (15A763) 0.4 .256 32 256 2
VSE
d (15A797) 0.5 256 16 128 4
VRE
e (15A799) 128 256 256 64 16
M. catarhallis (58L028) 32 64 64 8 32
acompounds tested in conjunction with compounds reported in ref. [24]
bV:
vancomycin, values first published in ref. [24],
cMRSA: methicillin resistant S.
aureus,
dVSE: vancomycin susceptible Enterococci,
eVRE: vancomycin resistant
Enterococci.
doi:10.1371/journal.pone.0039768.t001
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(2.2 mg, 1.25 mmol) was added H2O/CH3CN 1/1 (600 mL). This
was added to 4 (4 mg, 1.25 mmol) and subsequently, Cu-
SO4.5H2O (2.5 mg, 0.01 mmol) and NaAsc (2 mg, 0.01 mmol).
The solution was mixed and gently heated until all components
had dissolved, and the mixture was subject to microwave heating
for 5 min. at a constant temperature of 80uC. The solvents were
removed in vacuo and the crude mixture was subject to preparative
HPLC. 1 was purified and lyophilized for 3.3 mg of a white
powder in a yield of 53%. The identity of 1 was confirmed with
MS. HPLC Retention time =17.1 min. .98%; MS m/z: 1088.4
[M +4H]
4+, 1451.2 [M +3H]
3.
Vancomycin-peptide conjugate (2). Compound 3 (6 mg,
3.1 mmol) and peptide-azide 5 (6.3 mg, 2.4 mmol) were dissolved
in H2O/DMF 18/1 (950 mL). CuSO4.5H2O (3 mg, 0.012 mmol)
was added and mixed until dissolved, and NaAsc (6.1 mg,
0.03 mmol) was added and mixed until dissolved. The mixture
was subject to microwave heating for 5 min. at a constant
temperature of 80uC. Buffer A was added (1 mL) and the solution
was subject to preparative HPLC. 2 was purified and lyophilized
for 6.5 mg of a white powder in a yield of 59%. The identity of 2
was confirmed with MS. HPLC Retention time =15.7 min.
.98%; MS m/z: 1826.8 [M +2H]
2+.
Bacterial strains. Methicillin-resistant Staphylococcus aureus
MRSA (15A761, and 15A763), vancomycin susceptible Enterococci
(VSE, strain 15A797), and vancomycin resistant Enterococci (VRE,
strain 15A799) were clinical blood isolates obtained from the strain
collection of the University Medical Center (Utrecht, The
Netherlands) from a teaching hospital in Coimbra, Portugal. M.
catarrhalis (58L028) was obtained from Porto, Portugal.
Antibacterial Activity
MICs were determined by broth microdilution, utilizing CA-
MHB as described by the CLSI guidelines [National Committee
for Clinical Laboratory Standards 2002. 5th ed., M7-A5.]
(formerly the NCCLS guidelines). Experiments were performed
in triplicate and the mean is reported.
5(6)-Carboxyfluorescein leakage. Experiments were per-
formed as previously described [19,28]. The lipid composition used
was 60% DOPC:SM:DOPE (46:42:12), 40% cholesterol and 0.1%
lipid II. In short, large unilamellar vesicles (LUV’s) containing 5-6-
carboxyfluoresceinweremadebyextrusionofmultilamellarvesicles
10x through a polycarbonate membrane filter (0.2 mm) in 5-6-
carboxyfluorescein (50 mM, 10 mM Tris pH 7, 150 mM NaCl).
The LUV’s were separated from the extravesicular 5-6-carboxy-
fluoresceinsolutionusingSephadexG50.Thelipidconcentrationin
the LUV’s was determined after destruction of the vesicles and Pi
measurement. The change in fluorescence (excitation 492 nm,
emission 515 nm) was measured upon addition of differing concen-
trations of antibiotic to the vesicles for a period of 3 minutes. The
percentleakagewasdeterminedat80seconds,andthevesicleswere
destroyed with Triton-X100 detergent for maximum obtainable
leakageat160seconds.Meanvaluesincludingstandarddeviationof3
measurements arereported.
Lipid II dependant hemolysis. Lipid II (7.5 mL, 0.04 mM
in ethanol) was added to human red blood cells (hRBC, 1 mL, 1%
suspension in phosphate buffered saline (PBS)) while gently
vortexing. To 100 mL of this suspension was added the antibiotic,
and incubated for 20 min. at 37uC with gentle shaking. The
suspension was diluted with PBS (300 mL), centrifuged, and the
absorbance of the supernatant was measured at 405, and 540 nm.
Controls consisted of the preparation of the hRBC similar to
above but addition of 7.5 mL ethanol/1 mL, 1% suspension in
PBS buffer. Values for 0% and 100% hemolysis were obtained
using hRBC (100 mL) suspended in PBS, incubated as above,
diluted with PBS (300 mL) (0% hydrolysis), or with water (300 mL)
(100% hemolysis). Experiments were performed in duplicate and
the mean is reported.
Supporting Information
Figure S1 HPLC traces of vancomycin-peptide conju-
gates.
(TIF)
Figure S2 Targeted hemolysis. Erythrocytes containing
lipid II (0.1%), were treated with 1 (n), 2 (#), nisin (%),
4 (*) and 5 (e). Vesicles without lipid II were treated with 1 (m),
2(N), nisin (&), 4 (6), 5 (X), and vancomycin (+).
(TIF)
Figure 3. Amount of hemolysis from erythrocytes with and without lipid II, after treatment with nisin (10 mM) compound 1 (10 mM),
and compound 2 (50 mM).
doi:10.1371/journal.pone.0039768.g003
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VRE, and synthesis of the Nisin(1-12)-peptide conjugate.
(DOC)
Table S1 Minimum inhibitory concentration (MIC, mg/
mL) of Nisin(1-12)-peptide derivatives.
(DOCX)
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